Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects

NCT00498654 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Typhoid Fever

Interventions

BIOLOGICAL: Ty800 (Salmonella typhi) Oral Vaccine

Sponsor

Avant Immunotherapeutics